LL-37
A human cathelicidin antimicrobial peptide studied in laboratory research; not FDA-approved.
What it is
LL-37 is the human body's own antimicrobial peptide — part of the innate immune system, produced in skin and immune cells, capable of disrupting bacterial membranes directly. As biology it is important and heavily studied.
As a product, it's a lab reagent being sold as a biohack. Research interest in antimicrobial peptides as future drugs is real, but LL-37 itself has complex, context-dependent roles — including in inflammation and autoimmunity — that make casual self-administration a genuinely strange bet. No human therapeutic program supports it.
What researchers have actually studied it for
Innate immune defense, wound biology and inflammation in laboratory research; a molecule of scientific interest, not a developed therapy.
How it works
The only human cathelicidin: a 37-amino-acid amphipathic helix that physically disrupts microbial membranes while separately signaling to immune cells — recruiting them, modulating inflammation, influencing wound biology. Its effects flip with concentration and context, which is exactly why 'supplementing' it is conceptually confused.
The molecule itself
A 37-residue amphipathic alpha-helix beginning with two leucines (hence the name) — the human cathelicidin, cleaved from the precursor hCAP18. Its helix physically inserts into microbial membranes; the same structural bluntness underlies its context-dependent effects on human cells.
Where it came from
Cloned in 1995 during the antimicrobial-peptide wave that followed cecropin and defensin discoveries, LL-37 became one of immunology's most-studied molecules — thousands of papers spanning infection, wound healing, psoriasis and autoimmunity. Therapeutic development has focused on derivatives and topical concepts, none of which is the injectable vial online.
The timeline
1995
Cloned during the antimicrobial-peptide discovery wave.
2000s
Immunomodulatory roles mapped; disease associations (psoriasis, rosacea) established.
2010s
Derivative and topical therapeutic concepts explored; systemic use never developed.
2020s
Gray-market adoption as an 'immune peptide.'
What the research record actually contains
- Vast basic-science literature on membrane disruption and immune signaling.
- Disease-association studies: elevated LL-37 activity in psoriasis, rosacea and some autoimmune states.
- Early exploratory work on topical derivatives (e.g. wound care) — no approved therapy, no systemic human program.
What could change this assessment
Antimicrobial-peptide therapeutics remain a real field — engineered derivatives, topical concepts, resistance-era interest. LL-37 itself is the template molecule, not the product; nothing points toward systemic human use.
What's known about risks
Systemic self-administration has no human data, and the association of excess LL-37 activity with inflammatory skin disease is a standing caution the marketing never mentions. This is a molecule whose dose- and context-dependence is the central scientific finding about it.
Where it stands legally
No approved product anywhere; research-reagent channel only.
Worth asking a licensed provider
- 1.What infection or immune concern am I actually trying to address, and what's the evaluated route?
- 2.Am I aware elevated LL-37 activity is a feature of inflammatory diseases, not just defense?
- 3.If wound healing is the issue, what's the proper work-up?
Common claims, corrected
“It's a natural antibiotic you can supplement.”
Reality: It's a locally-acting, tightly-regulated defense molecule whose excess characterizes inflammatory disease — systemic supplementation inverts its biology.
“More LL-37, better immunity.”
Reality: Psoriasis and rosacea feature elevated LL-37 activity; the molecule's dose- and context-dependence is its central scientific finding.
LL-37 FAQ
What does LL-37 do in the body?
It kills microbes directly, signals to immune cells, and participates in wound-adjacent inflammation. It's a busy, context-dependent molecule — which is exactly why 'more of it' isn't automatically good.
Is LL-37 a treatment for infections?
No approved therapy uses it. Antimicrobial peptides are an active research field, but LL-37 injections from research-chemical sites have no human evidence behind them.
Are there risks to taking LL-37?
Elevated LL-37 activity appears in inflammatory and autoimmune conditions like psoriasis and rosacea — correlation that should give any 'boost your LL-37' pitch pause. Human safety data for supplementation doesn't exist.
Why is vitamin D mentioned with LL-37?
Vitamin D signaling upregulates cathelicidin expression — a legitimate, well-studied connection that makes adequate vitamin D the evidence-adjacent way to support this pathway, no vial involved.
Could LL-37 derivatives become drugs?
Engineered antimicrobial peptides are in active development against resistant organisms — narrow, topical and clinical-context uses, which is what responsible development of blunt-instrument biology looks like.